Avatar for Intellia Therapeutics



At intellia, we are building a full-spectrum, product-driven biotechnology company focused on developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. our approach to advancing the broad potential of genome editing includes our plans to enhance our crispr system. on the in vivo side, our systemic lipid nanoparticle or lnp-based delivery system, has the potential to unlock treatment of genetic diseases to both selectively knock out disease-causing genes and introduce targeted insertion of a functional gene. we are also focused on engineering t cell therapies to preserve normal cell physiology. ​our approach is designed to improve safety and efficacy by engineering cell therapies​ that are more precise, potent and persistent.
Total raised


Funded over

2 rounds

Latest round

Series B (Sep 2015)

Fsa limits 2020 (per year)

401(k) limits 2020 (per year)

Employee stock purchase plan (espp)

Transportation limits 2020 (per month

Tuition reimbursement